Champions Oncology, Inc. Releases Q3 2026 Financial Results: Key Insights for Investors

Champions Oncology, Inc. has published its Form 10-Q for the quarterly period ended January 31, 2026, offering a comprehensive look at its financial health and operational performance. Below, we break down the most important information that shareholders and potential investors should be aware of, including items that may be price-sensitive or impact the company’s share value.

Key Highlights from the Q3 2026 Report

• Reporting Status: The company confirms it has filed all required reports and has been subject to SEC reporting requirements for the past 90 days. Champions Oncology is classified as a non-accelerated filer and a smaller reporting company.
• Financial Statements: The condensed consolidated balance sheet and income statement reveal crucial updates regarding assets, liabilities, equity, and net income/loss.

Financial Position

• Total Assets: \$28.45 million as of January 31, 2026, compared to \$28.57 million at the prior period end.
• Total Liabilities: \$24.17 million, an increase from \$24.80 million previously, indicating a slight rise in obligations.
• Stockholders’ Equity: \$4.38 million, down from \$4.77 million at the prior period end. This reflects a decrease in the equity base, which may be of concern to investors, especially in the context of ongoing profitability and capital management.
• Noncontrolling Interest: Remains zero, meaning all equity is attributable to the company’s shareholders.

Share Structure and Capital Transactions

• Common Shares Outstanding: 14,007,159 shares as of January 31, 2026.
• Treasury Shares: 120,333 shares, valued at \$708,000, held in treasury.
• Stock-Based Compensation: \$423,000 recognized during the quarter, which impacts the overall equity and may dilute existing shareholdings if options are exercised.
• Stock Option Exercises: 97,905 shares issued during the quarter, generating \$3,000 in proceeds. This increase in outstanding shares may dilute existing shareholders but also signals insider confidence in the company.

Profitability and Earnings

• Net Income (Loss): The company reported a net loss of \$466,000 for the quarter. This is a reversal from prior periods where net income was reported, possibly signaling operational or market challenges.
• Earnings Per Share (EPS): Basic EPS was (\$0.04) for the quarter, while diluted EPS was also (\$0.04). These negative earnings figures are price-sensitive and could impact investor confidence and share price.
• Weighted Average Shares Outstanding: 13,886,797 for basic EPS calculation.

Other Key Items

• Market Risk Disclosures: The company provides quantitative and qualitative disclosures about market risk, though no material changes are noted.
• Unregistered Sales of Equity Securities: No unregistered sales reported, indicating compliance with SEC regulations.
• Defaults Upon Senior Securities: No defaults reported.
• Shell Company Status: The company confirms it is not a shell company.

Potential Price-Sensitive Factors

• Net Loss and EPS Decline: The swing to a net loss and negative EPS could be seen as a negative by investors, potentially impacting share price.
• Decrease in Stockholders’ Equity: A shrinking equity base may raise concerns about future capital structure and solvency.
• Stock-Based Compensation & Option Exercises: The issuance of new shares for option exercises and stock-based compensation may dilute existing shareholders, which is a price-sensitive issue.

Conclusion

Champions Oncology, Inc.’s Q3 2026 results show a challenging quarter with a reported net loss, decreased equity, and ongoing stock-based compensation. Investors should closely monitor future earnings, capital management, and operational performance, as these factors are likely to influence share value moving forward.

Disclaimer: This article is for informational purposes only and should not be construed as investment advice. The information is based on the company’s official SEC filings as of January 31, 2026. Investors should conduct their own research and consult with professional advisors before making any investment decisions.

View CHAMPIONS ONCOLOGY, INC. Historical chart here